Bracco Expands Global CEUS Collaboration with Second Steering Committee Meeting

Bracco has convened the second edition of its Global CEUS Steering Committee, bringing together international experts in contrast-enhanced ultrasound (CEUS) to foster sustained scientific exchange and help shape a shared vision for the future development and application of the technology. The meeting, held in Munich in conjunction with the EUROSON School, marks the latest step in a global initiative that began in China in 2025, when Bracco first assembled CEUS experts from across specialties and geographies.

This year's gathering brought together 14 international CEUS experts, including representatives from Bracco Medical and R&D. Spanning clinical specialties and geographies, participants explored emerging clinical needs, scientific developments and research opportunities that could influence the continued evolution and adoption of CEUS.

A Durable, Multidisciplinary Network

The Steering Committee is designed as a durable, multidisciplinary network connecting the international CEUS community and Bracco through ongoing engagement and cross-border collaboration. Expert perspectives and insights generated through the initiative will help identify areas for further research, evidence generation and innovation across CEUS applications.

"As CEUS continues to expand across clinical settings, there is a valuable opportunity to bring together experts from different specialties and regions and learn from their diverse perspectives,“ said Antonella Filippone, Head of Medical Affairs & Scientific Information at Bracco. ”Through the Global CEUS Steering Committee, we aim to build lasting relationships and foster ongoing scientific exchange. By bringing together multidisciplinary expertise and perspectives, we can help advance the clinical adoption of CEUS and, where appropriate, support more patient-friendly diagnostic pathways through a non-invasive imaging approach that has the potential to improve patient experience and support clinical decision-making."

Scientific Focus: Super-Resolution, AI and New Software

Discussions at the meeting focused on scientific and technological developments that could influence the future of CEUS, including super-resolution imaging, new software applications and artificial intelligence. Experts explored the potential implications for diagnostic and potentially therapeutic applications, as well as opportunities to optimize clinical workflows and address healthcare and economic considerations related to CEUS adoption.

"Scientific progress depends on understanding not only what is possible today, but also how evolving clinical needs and emerging technologies may shape what comes next,“ said Victor Jeannot, R&D Program Manager at Bracco. ”Bringing together expertise from different disciplines can help identify important questions for future research and provide a broader view of emerging technologies and their potential role in CEUS. That perspective can help focus future investigation on areas with the potential to advance the field."

Annual Convening and Broader Engagement

The Global CEUS Steering Committee will convene annually to foster ongoing engagement and collaboration among participating experts and Bracco. The committee will also support engagement with the broader scientific community, including scientific societies. By connecting expertise across disciplines and regions, Bracco aims to contribute to a broader global dialogue around CEUS and strengthen its long-term collaboration with the international CEUS community.

Industry Implications

The initiative underscores Bracco's strategic push to position CEUS as a more prominent tool in diagnostic imaging. By creating a structured, recurring forum for international experts, the company is investing in relationship-building and evidence generation that could accelerate clinical adoption. The emphasis on super-resolution imaging, AI and workflow optimization signals where the company sees the next frontier for contrast-enhanced ultrasound, while the focus on patient-friendly, non-invasive pathways aligns with broader healthcare trends toward reducing procedural burden and improving patient experience.

About Bracco

Bracco Group, founded in 1927, is a global leader in diagnostic imaging, committed to advancing healthcare and improving people's lives by shaping the future of prevention and precision medicine. The company operates in the healthcare sector across more than 100 countries with a workforce of over 4,000 employees and consolidated annual revenues of approximately €2 billion, with a global footprint.

With a strong commitment to innovation—investing around 9% of its reference turnover in Research & Development—Bracco develops and provides a broad portfolio of pharmaceutical products for diagnostic imaging, including contrast agents for X-ray, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI), as well as microbubbles for Contrast Enhanced Ultrasound (CEUS), and Molecular Imaging through radioactive tracers and novel PET imaging agents, alongside AI-based solutions. It is also a global market leader in advanced contrast management technologies for cardiovascular angiography and radiology imaging.